SafeMinds has actively critiqued much of the research on the vaccine-autism link since 2000. Generation Rescue has provided two websites, fourteenstudies.org and putchildrenfirst.org, that provide critiques of the flaws of studies that are often used to refute the vaccine-autism link. Those websites include critiques written by SafeMinds, such as Analysis and Critique of the CDC’s Handling of the Thimerosal Exposure Assessment Based on VSD Information written as critique of the Verstraetten study. You will find other commentaries and critiques by SafeMinds below.
Urinary Excretion Study – SafeMinds Commentary (2/22/12)
Brief: Environment vs. Genetics
Why The Autism Epidemic Demands a New Approach
Background, Supporting Research and Analysis of Current Research Funding
Vaccines and Autism: What do Epidemiological Studies Really Tell Us?
This paper examines the epidemiological studies surrounding “autism and the MMR vaccine” and “autism and thimerosal”. It explains in detail the conflicts of interest, poor designs and unsupported conclusions in 16 different studies related to autism and vaccines. It includes the opinions of other authorities on these studies as well.
On-Time Vaccine Receipt in the First Year Does Not Adversely Affect Neuropsychological Outcomes (June 2010)
SafeMinds Safety First Comment to National Vaccine Program
SafeMinds Response to National Vaccine Plan of 2008 Draft (March 2009)
Latest Autism Gene Findings… Not Much (April 2009)
There’s a familiar rhythm to the most prominent autism gene hunt publications. Their authors hype their newly minted study aggressively in the media. The prestigious journals that publish them lend their imprimatur to press releases that say, “this study is a big deal.” The findings sound impressive in the press release (and the authors get plenty of time on camera and in leading newspapers to tell us how truly impressive they are). In the meantime–in papers that are so densely written that making sense of what they really say requires far more reflection than the media hype cycle permits–skillfully concealed evidence reveals the truly important new in the findings: the authors whisper quietly (if at all) that the new analysis negates the most important findings of some of the most prominent previous gene hunts, while crucial detail on their new findings is often relegated to “supplementary material” that’s not available on the publication date. Read more.
SafeMinds Sponsors and Attends 25th International Neurotoxicology Conference
NIH & AUTISM: A Case Study in Barriers to Progress in Environmental Medicine
October 2008 Authored by Sallie Bernard, Mark Blaxill and Theresa Wrangham
Read paper or poster.
SafeMinds and National Autism Association – NIEHS-Sponsored Symposium on Environmental Factors in Neurodevelopmental Disorders (August 2005)
In August 2005, a two-day symposium was held in Bethesda, Maryland on the role of environmental factors in the pathogenesis of autism spectrum disorders and related neurodevelopmental conditions. Dr. Kenneth Olden – then the director of NIEHS – conceived the idea for the conference, and the meeting was sponsored by NIEHS. Two autism research groups, the Coalition for SafeMinds and the National Autism Association, co-organized the meeting with a team of researchers they recruited to the effort.
MMR and Autism in Perspective: The Denmark Story (2004)
Authored by Carol Stott, Ph.D.; Mark Blaxill; Andrew J.Wakefield, M.B., FRCS for the Journal of American Physicians and Surgeons
Autism and related developmental disorders, once rare, are now becoming a common problem in Western countries. Although frequently catastrophic in their effects, the current crisis has come up against a “duck-and-cover” mentality from many a dusty corner of conventional medical wisdom. Read more.
Something is Rotten in Denmark (May 2004)
An Analysis of the Failures and Conflicts of Interest in Several Studies Used by IOM Vaccine Safety Committee Report. View Power Point
Generation Zero Full Analysis with Charts (2004)
Thomas Verstraeten’s First Analyses of the Link Between Vaccine Mercury Exposure and the Risk of Diagnosis of Selected Neuro-Developmental Disorders Based on Data from the Vaccine Safety Datalink: November-December 1999. Click here for full analysis with charts, click here for Generation Zero Synopsis.
Analysis and Critique of the CDC’s Handling of the Thimerosal Exposure Assessment Based on VSD Information (October 2003)
View Power Point
Analysis of the Danish Autism Registry Data Base in Response to the Hviid et al Paper on Thimerosal in JAMA (October 2003)
A large percentage of diagnosed autism cases are lost from the Danish registry each year. In the ten years preceding 2000, 815 cases were lost, more than the 710 remaining in the registry in 2000. The vast majority of those lost cases would represent older children in the 2000 registry. Since the relative risk of the Hviid study is based on finding fewer older thimerosal-exposed children than younger unexposed children, the validity of their conclusion exonerating thimerosal in autism is questionable. More likely, the finding is a result of missing records rather than true lower incidence rates among the exposed group. Read more.
Danish Thimerosal-Autism Study in Pediatrics: Misleading and Uninformative on Autism-Mercury Link (September 2003)
A report by Madsen et al. published by the American Academy of Pediatrics in their journal Pediatrics claims to provide evidence against a link between autism rates and the mercury in thimerosal, a preservative used in childhood vaccines. Unfortunately, the study analysis is full of flaws and inaccuracies, invalidating the conclusions regarding thimerosal. The study adds little of value to the scientific literature on autism and mercury. Read more.
SafeMinds Press Release: Vaccine Health Officials Manipulate Autism Records to Quell Rising Fears over Mercury in Vaccines: Safe Minds Cites Unscientific Trending Techniques and Conflicts of Interest, Call Study’s Conclusions Doubtful
Commentary on Croen et al. (2002) The Changing Prevalence of Autism in California (April 2003)
Authored by Blaxill, Baskin and Spitzer Journal of Autism and Developmental Disorders, Vol. 33, No. 2, April 2003
Lisa Croen and colleagues (Croen, Grether, Hoogstrate, & Selvin, 2002) suggest that the real incidence of autism has not increased. They propose instead that a pattern of “diagnostic substitution” has moved Californian patients who would previously have been diagnosed as mentally retarded (Croen, Grether, & Selvin, 2001) into the autism category. Their calculations purport to demonstrate that over 100% of the increase in autism from 1987–1994 is an artifact of changes in diagnostic practices. In your editorial commentary, Eric Fombonne praises the study, and claims “Croen et al. carefully analyzed the California dataset.” Read more.
30 Years of Autism = $7 Trillion in Costs
Next Decade Will Add More Trillions to Looming Public Financial Burden: The lifetime cost of autism for U.S. cases identified in the 30 years between 1990 and 2019 is estimated to be $7 trillion. If costs for the next decade 2020-2029 are included, the lifetime cost will reach up to $15 trillion. The findings were reported in a new study in the journal Research in Autism Spectrum Disorders. In “The Lifetime Social Cost of Autism: 1990–2029”, authors Janet Cakir, Richard Frye, and Stephen Walker compiled findings from peer-reviewed published studies on the number of cases of autism for the decades 1990-2019 and the lifetime cost of autism per person in the U.S.
Potential Anti-inflammatory Treatment for Autism
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social interactions and communication. 1 ASD affects about 1 in 59 children 2 and is estimated to reach 1 in 40 children in 2025. 3 The complexity of the factors involved in the clinical picture of ASD, along with the lack of reliable biomarkers 4 and specific pathogenesis 5 has prevented the development of effective treatments.
Autism Prevalence – Examining the Myths and Truths
SafeMinds interviews the New Jersey investigator for the U.S. Centers for Disease Control and Prevention’s (CDC) autism prevalence report of 1 in 59 children, examining the truths and myths behind the latest numbers from the Federal Government. The big news for May was the release of new autism prevalence numbers from the Federal Government. The CDC study by the Centers for Disease Control & Prevention (CDC) found that 1 in 59 children have autism, up from the 1 in 68 they reported just two years ago. This alarming increase compelled SafeMinds to call for an emergency meeting with the U.S. Department of Health and Human Services (HHS). Along with other autism organizations, SafeMinds is demanding a Federal Autism Strategic Plan that address the urgent crisis of autism.
Autism & Mental Health: Problems & Solutions
Two new studies point to higher and growing healthcare costs for autism spectrum disorders (ASD) across the lifespan, particularly in the area of mental health. A new model program in New York might have an answer to this critical problem. A new study reports that children with autism were up to 30 times more likely to use emergency departments (ED) than youth without ASD. Many of those visits were for non-urgent ED visits, which is a costly way to provide routine healthcare. Up to 13 percent of visits were for behavioral or psychiatric problems, far more than for children without autism, for whom less than two percent of visits were for psychiatric problems. Youth with ASD were also likely to have repeat visits to the ED and more likely to be admitted to a psychiatric unit or medical floor. The study was a review of the literature published between 1985 and 2016.
Why We Can and Should Focus on Autism Prevention
In light of the recent increase in autism from 1 in 68 to 1 in 59 children in just two years, a new video by scientist Bruce Lanphear it worth watching and sharing. The video makes the case for preventing chronic diseases like autism rather than chasing down genes or finding cures. In “Cause or Cure. Is the relentless pursuit of a cure hazardous to our health?”, Dr. Lanphear says that more health and science dollars need to be directed to prevention. His approach to prevention is identifying environmental exposures that promote disease and then investing in removing these exposures.
Two Treatments with Positive Results and the High Cost of Autism
Two abstracts being presented this week at the annual conference of the American Academy of Neurology report positive outcomes from two treatments for autism. A third article on healthcare utilization reports double the cost for adults with autism. A MitoCocktail was tested in eleven children with autism and mitocondrial (mt) dysfunction. Mt dysfunction is common in autism. The MitoCocktail contained carnitine, coenzyme Q10 and alpha-lipoic acid. Investigators Craig Newschaffer and colleagues at Drexel University conclude: “This small pilot study supports the hypothesis that in ASD MitoCocktail may have a therapeutic benefit, improving mt function and maladaptive behavior and speech. Larger placebo-controlled trials are needed to demonstrate efficacy.”
